UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Safety and effectiveness of neuraminidase inhibitors in situations of pandemic and/or novel/variant influenza: a systematic review of the literature, 2009-15

Journal of antimicrobial chemotherapy, 2017-06, Vol.72 (6), p.1556-1573

2017

Volltextzugriff (PDF)

POSC74 Considerations for Mental Health Effects in Health Economic Analyses

Value in health, 2022-01, Vol.25 (1), p.S101-S101

2022

Volltextzugriff (PDF)

ERG expression is associated with increased risk of biochemical relapse following radical prostatectomy in early onset prostate cancer

Clinical & translational oncology, 2014-11, Vol.16 (11), p.973-979

2014

Volltextzugriff (PDF)

PNS15 COVARIATE ADJUSTMENT IN INDIRECT TREATMENT COMPARISON (ITC): HOW TO BLEND THE USEFUL WITH THE AGREEABLE

Value in health, 2019-11, Vol.22, p.S765-S765

2019

Volltextzugriff (PDF)

EE212 Comprehensive Review of Methods to Estimate Market Share Uptakes in Budget Impact Models

Value in health, 2023-06, Vol.26 (6), p.S97-S97

2023

Volltextzugriff (PDF)

POSB423 Incident Versus Prevalent Population: Review of Guidelines to Estimate the Eligible Population for Budget Impact Analysis

Value in health, 2022-01, Vol.25 (1), p.S274-S274

2022

Volltextzugriff (PDF)

PCN82 Cost-Effectiveness of Once Weekly Selinexor-Bortezomib-Dexamethasone (XVD) in Previously Treated Multiple Myeloma (MM)

Value in health, 2021-06, Vol.24, p.S34-S34

2021

Volltextzugriff (PDF)

PNS39 USING CURE MODELS IN ECONOMIC ANALYSES: A REVIEW AND CONCEPTUAL GUIDELINE

Value in health, 2020-05, Vol.23, p.S290-S291

2020

Volltextzugriff (PDF)

EE534 Economic Evaluations of HIV-1 Disease in South Africa – A Targeted Literature Review

Value in health, 2022-12, Vol.25 (12), p.S160-S161

2022

Volltextzugriff (PDF)

PCR52 Adherence/Compliance to HIV–1 Treatment Regimens in South Africa — A Targeted Literature Review

Value in health, 2022-12, Vol.25 (12), p.S399-S400

2022

Volltextzugriff (PDF)

EE268 Per-Member Per-Month (PMPM) Expenditure Value in Oncology: Updating a Focused Literature Review

Value in health, 2022-12, Vol.25 (12), p.S106-S106

2022

Volltextzugriff (PDF)

PCN28 Network Meta-Analysis (NMA) of Once Weekly Selinexor-Bortezomib-Dexamethasone (XVD) in Previously Treated Multiple Myeloma (MM)

Value in health, 2021-06, Vol.24, p.S23-S23

2021

Volltextzugriff (PDF)

PCN15 Increasing Disease Complexity Poses Challenges for Indirect Treatment Comparisons: An Example in Relapsed and Refractory Multiple Myeloma (RRMM)

Value in health, 2021-06, Vol.24, p.S21-S21

2021

Volltextzugriff (PDF)

Matching-adjusted indirect treatment comparison of ribociclib and palbociclib as first-line treatments for HR+, HER2– ABC

Annals of oncology, 2017-09, Vol.28, p.v82-v82

2017

Volltextzugriff (PDF)

PCN46 COST-EFFECTIVENESS MODEL COMPARING SUBA-ITRACONAZOLE (SUBA-ITRA) VERSUS CONVENTIONAL ITRACONAZOLE (ITRA) FOR TREATING SYSTEMIC MYCOSES IN THE U.S

Value in health, 2019-05, Vol.22, p.S64-S64

2019

Volltextzugriff (PDF)

PCN49 COST-EFFECTIVENESS MODEL COMPARING EXPANDED UMBILICAL CORD BLOOD TRANSPLANTS WITH OTHER HSCT STRATEGIES FOR PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES

Value in health, 2019-05, Vol.22, p.S65-S65

2019

Volltextzugriff (PDF)

PCN52 BUDGET IMPACT OF SUBA-ITRACONAZOLE CAPSULES (SUBA-ITRA) FOR THE TREATMENT OF SYSTEMIC MYCOSES IN THE U.S

Value in health, 2019-05, Vol.22, p.S65-S65

2019

Volltextzugriff (PDF)

PSY19 - USING A BAYESIAN NETWORK META-ANALYSIS (NMA) TO COMPARE FERRIC MALTOL TO TREATMENTS FOR IRON DEFICIENCY AND IRON DEFICIENCY ANAEMIA EXCLUDING CHF AND CKD PATIENTS

Value in health, 2018-10, Vol.21, p.S439-S439

2018

Volltextzugriff (PDF)

PSY217 - INCREMENTAL QUALITY-ADJUSTED SURVIVAL ANALYSIS WHEN NO HEAD TO HEAD DATA ARE AVAILABLE: A CASE STUDY OF MIDOSTAURIN (MIDO) VERSUS STANDARD OF CARE (SOC) IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS (ASM)

Value in health, 2018-10, Vol.21, p.S473-S473

2018

Volltextzugriff (PDF)

CN6 - COST-EFFECTIVENESS MODEL OF MIDOSTAURIN (MIDO) VERSUS STANDARD OF CARE (SOC) IN PATIENTS WITH NEWLY DIAGNOSED FLT3 MUTATION-POSITIVE (FLT3+) ACUTE MYELOID LEUKEMIA (AML): A FRENCH PERSPECTIVE

Value in health, 2018-10, Vol.21, p.S4-S5

2018

Volltextzugriff (PDF)

PSY15 - Bayesian Network Meta-Analysis of Treatments in Iron Deficiency Anaemia (IDA)

Value in health, 2018-05, Vol.21, p.S247-S247

2018

Volltextzugriff (PDF)

Bayesian Network Meta-Analysis of Treatments in Iron Deficiency Anaemia (IDA)

Value in health, 2018-05, Vol.21, p.S247

2018

Volltextzugriff (PDF)

US Budget Impact Model for Selinexor, Bortezomib, and Dexamethasone for the Treatment of Previously Treated Multiple Myeloma

ClinicoEconomics and outcomes research, 2021-01, Vol.13, p.493-502

2021

Volltextzugriff (PDF)

CE2 - Cost-Effectiveness Analysis of Midostaurin (MIDO) with Standard Chemotherapy (SOC) for Acute Myeloid Leukemia (AML) in the United Kingdom (UK)

Value in health, 2017-10, Vol.20 (9), p.A399-A399

2017

Volltextzugriff (PDF)

COST CONSEQUENCE MODEL COMPARING ELTROMBOPAG AND ROMIPLOSTIM FOR ADULT PATIENTS WITH PREVIOUSLY-TREATED CHRONIC IMMUNE THROMBOCYTOPENIA

Value in health, 2017-05, Vol.20 (5), p.A220

2017

Volltextzugriff (PDF)

1 – 25 von 332

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(298)
Mit Volltextzugriff
(300)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(332)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(190)
Life Sciences & Biomedicine
(158)
Animals
(129)
Biochemistry & Molecular Biology
(66)
Mice
(50)
Humans
(48)
Female
(41)
Male
(41)
Evolutionary Biology
(40)
Molecular Sequence Data
(39)
Evolution
(38)
Biological And Medical Sciences
(36)
Ecology
(34)
Environmental Sciences & Ecology
(31)
Fundamental And Applied Biological Sciences. Psychology
(30)
Base Sequence
(29)
Selenium
(29)
Selenoproteins
(29)
Biological Evolution
(27)
Biology
(24)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Safety and effectiveness of neuraminidase inhibitors in situations of pandemic and/or novel/variant influenza: a systematic review of the literature, 2009-15

POSC74 Considerations for Mental Health Effects in Health Economic Analyses

ERG expression is associated with increased risk of biochemical relapse following radical prostatectomy in early onset prostate cancer

PNS15 COVARIATE ADJUSTMENT IN INDIRECT TREATMENT COMPARISON (ITC): HOW TO BLEND THE USEFUL WITH THE AGREEABLE

EE212 Comprehensive Review of Methods to Estimate Market Share Uptakes in Budget Impact Models

POSB423 Incident Versus Prevalent Population: Review of Guidelines to Estimate the Eligible Population for Budget Impact Analysis

PCN82 Cost-Effectiveness of Once Weekly Selinexor-Bortezomib-Dexamethasone (XVD) in Previously Treated Multiple Myeloma (MM)

PNS39 USING CURE MODELS IN ECONOMIC ANALYSES: A REVIEW AND CONCEPTUAL GUIDELINE

EE534 Economic Evaluations of HIV-1 Disease in South Africa – A Targeted Literature Review

PCR52 Adherence/Compliance to HIV–1 Treatment Regimens in South Africa — A Targeted Literature Review

EE268 Per-Member Per-Month (PMPM) Expenditure Value in Oncology: Updating a Focused Literature Review

PCN28 Network Meta-Analysis (NMA) of Once Weekly Selinexor-Bortezomib-Dexamethasone (XVD) in Previously Treated Multiple Myeloma (MM)

PCN15 Increasing Disease Complexity Poses Challenges for Indirect Treatment Comparisons: An Example in Relapsed and Refractory Multiple Myeloma (RRMM)

Matching-adjusted indirect treatment comparison of ribociclib and palbociclib as first-line treatments for HR+, HER2– ABC

PCN46 COST-EFFECTIVENESS MODEL COMPARING SUBA-ITRACONAZOLE (SUBA-ITRA) VERSUS CONVENTIONAL ITRACONAZOLE (ITRA) FOR TREATING SYSTEMIC MYCOSES IN THE U.S

PCN49 COST-EFFECTIVENESS MODEL COMPARING EXPANDED UMBILICAL CORD BLOOD TRANSPLANTS WITH OTHER HSCT STRATEGIES FOR PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES

PCN52 BUDGET IMPACT OF SUBA-ITRACONAZOLE CAPSULES (SUBA-ITRA) FOR THE TREATMENT OF SYSTEMIC MYCOSES IN THE U.S

PSY19 - USING A BAYESIAN NETWORK META-ANALYSIS (NMA) TO COMPARE FERRIC MALTOL TO TREATMENTS FOR IRON DEFICIENCY AND IRON DEFICIENCY ANAEMIA EXCLUDING CHF AND CKD PATIENTS

PSY217 - INCREMENTAL QUALITY-ADJUSTED SURVIVAL ANALYSIS WHEN NO HEAD TO HEAD DATA ARE AVAILABLE: A CASE STUDY OF MIDOSTAURIN (MIDO) VERSUS STANDARD OF CARE (SOC) IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS (ASM)

CN6 - COST-EFFECTIVENESS MODEL OF MIDOSTAURIN (MIDO) VERSUS STANDARD OF CARE (SOC) IN PATIENTS WITH NEWLY DIAGNOSED FLT3 MUTATION-POSITIVE (FLT3+) ACUTE MYELOID LEUKEMIA (AML): A FRENCH PERSPECTIVE

PSY15 - Bayesian Network Meta-Analysis of Treatments in Iron Deficiency Anaemia (IDA)

Bayesian Network Meta-Analysis of Treatments in Iron Deficiency Anaemia (IDA)

US Budget Impact Model for Selinexor, Bortezomib, and Dexamethasone for the Treatment of Previously Treated Multiple Myeloma

CE2 - Cost-Effectiveness Analysis of Midostaurin (MIDO) with Standard Chemotherapy (SOC) for Acute Myeloid Leukemia (AML) in the United Kingdom (UK)

COST CONSEQUENCE MODEL COMPARING ELTROMBOPAG AND ROMIPLOSTIM FOR ADULT PATIENTS WITH PREVIOUSLY-TREATED CHRONIC IMMUNE THROMBOCYTOPENIA

Suchergebnisse filtern